|
|
ANA-HEp2 pattern evaluation in pancreatic cancer: What can the autoantibodies tell us? |
Amanda PB Albuquerque a , Amanda R Fernandes a , Angela LBP Duarte b , Henrique de Ataide Mariz b , Jose GCA Junior c , Luiz A Mattos d , Maira Galdino da Rocha Pitta a , Moacyr JBM Rego a , ∗ |
a Laboratory of Immunomodulation and New Therapeutical Approaches, Research Centre for Therapeutic Innovation Suely Galdino (NUPIT-SG), Federal University of Pernambuco, Recife, PE, Brazil
b Rheumatology Service, Hospital das Clínicas, Recife, PE, Brazil
c General Surgery Service, Hospital das Clínicas, Recife, PE, Brazil
d Oncology Service, Hospital das Clínicas, Recife, PE, Brazil
∗ Corresponding author.
E-mail address: moacyr.rego@ufpe.br (M.J. Rego).
|
|
|
Abstract Pancreatic neoplasms are mainly diagnosed by imaging methods and confirmed by biopsies [1]. Imaging techniques and the tumor markers carbohydrate antigen 19-9 (CA19-9) or carcinoembryonic antigen (CEA) used for follow-up, are expensive and of low sensitivity and specificity [2].
|
|
|
|
|
|
|
|